At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 34 enrolled
Drug / intervention
AMG 133drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label, Randomized, Parallel-arm, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Subjects
In Brief
A Phase 1 clinical trial evaluating AMG 133 for Healthy Participants. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of AMG 133 after single subcutaneous (SC) administration in healthy Japanese and Caucasian participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedSep 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedSep 24, 2021
Enrollment StartSep 10, 2021
Primary CompletionApr 8, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.8 years ago
Interventions
AMG 133drug
Solution for SC injection